The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

Table 1

Clinical and pathological characteristics.

Characteristics	Number	Percent (%)
Total patients	96	100.0
Gender
Male	78	81.3
Female	18	18.7
Years ≥ 65
Yes	26	27.1
No	70	72.9
Targeted therapy
Sunitinib	35	36.5
Sorafenib	37	38.5
No	24	25.0
Pathology
Clear cell	90	93.8
Papillary	5	5.2
Undifferentiated	1	1.0
Sarcomatoid dedifferentiation
Yes	11	11.5
No	85	88.5
T
T1-2	55	57.3
T3-4	41	42.7
N
N0	87	90.6
N1-2	9	9.4
G
G1-2	68	70.8
G3-4	28	29.2
Metastatic sites
Lung	55	57.3
Bone	39	40.6
Liver	8	8.3
Brain	4	4.2
Adrenal gland	14	14.6
Retroperitoneal lymph node	13	13.5
Supradiaphragmatic lymph node	4	4.2
Others	7	7.3
Metastatic organ
1	61	63.5
≥2	35	36.5
Disease-free interval
≤12 months	53	55.2
>12 months	43	44.8
Metastasectomy
Complete resection	31	32.3
Incomplete resection	11	11.5
No resection	54	56.3